Fulcrum Therapeutics, Inc. (FULC)

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that are developing for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-HbF, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and b-thalassemia. The company has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Current Quote*
Last: $17.600
Change: -1.700
Book: $4.193
Volume: 40,678

As Of: 01/22 13:00 ET
*Quotes delayed by 20min.

Graphs for FULC

3 Month Graph

6 Month Graph

1 Year Graph